Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders

  title={Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders},
  author={Mengting Jia and Qiwen Zhang and Zirong Qin and Runqing Lu and Xueke Tian and Jing Yang and Xiao-jian Zhang},
  journal={Frontiers in Pharmacology},
Posaconazole (PCZ) is effective in preventing and salvage treatment invasive fungal infections in patients with hematologic disorders. However, PCZ displays highly variable individual pharmacokinetics affecting its efficacy and safety. To investigate the correlation between PCZ concentration and efficacy and safety, the following key influencing factors were explored. A total of 285 trough plasma concentrations (Cmin) of 81 Chinese patients receiving PCZ oral suspension for prophylaxis or… Expand

Figures and Tables from this paper


Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
It is highlighted that voriconazole C(min) and C(Min)/C(N) are strongly influenced by CYP2C19 polymorphism, and gene-adjusted dosing is important to achieve therapeutic levels that maximise therapeutic response and minimise hepatotoxicity. Expand
Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration
Low posaconazole concentrations are common and are associated with breakthrough fungal infection, supporting the utility of monitoring posaconzole concentrations to ensure optimal systemic exposure. Expand
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
Posaconazole is a second-generation triazole agent with an extended spectrum of activity, which shows a high interindividual variability in its plasma levels, rendering dosing in many patients inconsistent or inadequate, and therapeutic drug monitoring, which is easily available in clinical practice, may improve treatment success and safety. Expand
Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study
The serum concentration of PCZ was related to the incidence of IFIs and a serum concentrations of >0.47 μg/ml is highly recommended to avoid IFIs after chemotherapy or HSCT and can be considered as an evaluation index for PCZ prophylaxis. Expand
Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma
Determining posaconazole concentrations in plasma will aid in assessing the need for either POS dose adjustment or switching to another systemic antifungal drug, thereby improving the effectiveness of prophylaxis against IFIs. Expand
Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies
Posaconazole was well tolerated; however, LFT abnormalities were frequent and TDM can be helpful to avoid underexposure to the drug and increase its efficacy in preventing IFI. Expand
Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.
This study highlights the major impact of PPI administration on PSZ blood plasma levels and stresses the risk of non-effective prophylaxis during induction treatment of AML. Expand
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
Posaconazole concentrations in patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy in a clinical setting were determined by high-performance liquid chromatography and a prediction basis for mean posaconazoles concentrations in AML/MDS patients was developed. Expand
Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
Therapeutic drug monitoring practice of posaconazole can be improved by increasing the implementation rate of dose recommendation by a multidisciplinary antifungal stewardship team. Expand
Posaconazole trough concentrations are not influenced by inflammation: A prospective study.
Longitudinal data analysis showed that more frequent therapeutic drug monitoring of posaconazole during inflammation or after an infection subsides is not necessary, and Posaconazoles concentrations are not influenced by inflammation, reflected by CRP concentration. Expand